Use of medication by young people with attention-deficit/hyperactivity disorder by Sawyer, M. et al.
 PUBLISHED VERSION  
 
 
Sawyer, Michael Gifford; Rey, Joseph M.; Graetz, Brian William; Clark, J. J.; Baghurst, 
Peter Adrian  
Use of medication by young people with attention-deficit/hyperactivity disorder Medical 
Journal of Australia, 2002; 177(1):21-25 
 
























This document has been archived with permission from the editor of the Medical 




MJA Vol 177 1 July 2002 21
RESEARCH
The Medical Journal of Australia ISSN:
0025-729X 1 July 2002 177 1 21-25
©The Medical Journal of Australia 2002
www.mja.com.au
Research
THERE IS CONCERN about the increas-
ing use of stimulant medication in Aus-
tralia and other countries.1-3 In the
United States, rates of stimulant use
increased 2.5 times from 1990 to 1995.4
Comparable information at a national
level is not available in Australia; how-
ever, Valentine et al5 reported marked
increases in the use of stimulants in
Western Australia and New South
Wales in the early 1990s.
There is good evidence for the effec-
tiveness of stimulant medication in
treating children with attention-deficit/
hyperactivity disorder (ADHD).6
Increased prescribing of stimulants may
reflect more frequent use of these medi-
cations to treat children appropriately
diagnosed with ADHD. Alternatively,
medical practitioners may be increas-
ingly using stimulants to treat a range of
childhood disorders. Only two previous
studies, both conducted in the United
States, have examined this issue.1,7 The
proportion of children with ADHD who
were receiving stimulants differed mark-
edly in the two studies: while Angold et
al7 reported that 72% of children with
ADHD in a North Carolina study were
being treated with stimulant medica-
tion, Jensen et al reported a figure of
12% in a survey of four US communi-
ties.1 Although the percentage of chil-
dren without  ADHD receiv ing
stimulants was small in both studies,
about half of the children receiving
stimulants in each study did not meet
the criteria for ADHD.
Our study had three aims: (i) to iden-
tify the percentage of children in Aus-
tralia with ADHD who were receiving
stimulants and other psychotropic med-
ications; (ii) to identify the number of
children without ADHD who were
receiving stimulants; and (iii) to identify





The participants were 3597 parents of
children aged 6–17 years who partici-
pated in the Child and Adolescent
Component of the Australian National
Survey of Mental Health and Well-
Being.8 The survey methodology has
been described in detail elsewhere.8,9 In
brief, the survey used a multistage prob-
ability sample of 4509 households to
select a representative sample of Aus-
tralian children aged 4–17 years (for
brevity, the term “children” will be used
to describe both young children and
adolescents). Between February and
May 1998, interviewers approached
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ABSTRACT
Objectives:  To examine the prevalence of psychotropic medication use by children 
with attention-deficit/hyperactivity disorder (ADHD) and children without ADHD. To 
identify factors associated with stimulant use by children in the community.
Design:  A representative, multistage probability sample of Australian households 
was conducted in 1998. Parents completed questionnaires assessing children’s 
mental health problems and health-related quality of life. They also completed a 
structured interview to identify children’s psychiatric disorders and their use of 
medications during the previous six months.
Participants:  Parent or main caregiver of 3597 children aged 6–17 years.
Main outcome measures:  Rates of use of stimulants (dexamphetamine and 
methylphenidate), antidepressants and clonidine by children.
Results:  Overall, 1.8% of children (95% CI, 1.5%–2.3%) were receiving stimulant 
medication. Of those with ADHD, 12.6% (95% CI, 9.8%–16.1%) were being treated 
with stimulants, 2.3% (95% CI, 1.3%–4.3%) with antidepressants, and 1.9% (95% 
CI, 1.0%–3.7%) with clonidine. Among children without ADHD, 0.5% (95% CI, 
0.3%–0.8%) were receiving stimulant medication. This represented 22.9% (95% CI, 
14.6%–34.0%) of all the children who were receiving stimulants. Variables 
significantly associated with stimulant use were being male, having ADHD, 
attending a paediatrician, and having higher scores on the Aggressive Behaviour 
and Attention Problems scales on the Child Behaviour Checklist.
Conclusions:  About 13% of Australian children with ADHD, and a substantial 
number of children without ADHD, are taking stimulants. The question of whether 
Australian children are being undertreated or overtreated with stimulant medication 
depends on the criteria used to assess the appropriateness of stimulant use. 
Additional information is needed to clarify when stimulants should be used to treat 
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randomly selected households, the
number chosen being proportional to
the population of each State or Terri-
tory. The response rate was 70%.
Ethical approval for the survey was
obtained from the Research Ethics
Committee at the Women’s and Chil-
dren’s Hospital, Adelaide.
Measures
In face-to-face interviews, parents com-
pleted the parent version of the Diag-
nostic Interview Schedule for Children
Version IV (DISC-IV).10-12 The DISC-
IV is a structured diagnostic interview
that can be used by lay interviewers. It is
designed to diagnose a range of mental
disorders in children (eg, ADHD, con-
duct disorder, depressive disorder)
based on DSM-IV criteria.10 Psycho-
metric properties are acceptable: the
test–retest reliability for ADHD was
0.79 (kappa), with a validity of 0.72
(kappa).12 Impairment criteria (out-
lined in DSM-IV) were not employed in
the diagnostic assessment of ADHD
because their use with the DISC-IV is
still under development. However, sub-
sequent analyses have shown that use of
the impairment criteria makes little dif-
ference to the number of children diag-
nosed as having ADHD, and does not
alter the relationship between the pres-
ence of ADHD and the use of stimu-
lants.
Parents were also asked to fill out a
Child Behaviour Checklist (CBCL),13 a
self-completed written questionnaire
that assesses the number of emotional
and behavioural problems experienced
by children in a range of areas. Ratings
are summarised as scores on a Total
Behaviour Problem Scale (incorporat-
ing all the problem items on the check-
list), an Externalising Scale (identifying
disruptive behaviour problems) and an
Internalising Scale (identifying emo-
tional problems). There are eight other
scales that rate specific emotional and
behavioural problems (eg, anxiety/
depressive problems, aggression prob-
lems, attention problems). Substantial
information is available about the psy-
chometr ic characteristics of the
CBCL.13
In face-to-face interviews, parents
were also asked about what help their
children had received for emotional and
behavioural problems during the previ-
ous six months (eg, services attended,
medications prescribed). Parents who
reported that their child had received
medication were asked to show the
interviewer the child’s medicine so that
the name could be correctly recorded.
Statistical analysis
We first examined the prevalence of
stimulant use according to sex and diag-
nosis. Prevalence estimates were
weighted to reflect (minor) deviations of
the sample from the characteristics of
the Australian population of children
aged 4–17 (based on Australian Bureau
of Statistics estimates as at 30 June
1998).
Subsequently, we investigated differ-
ences between groups of children using
stimulants and those not using stimu-
lants. Logistic regression analyses were
used to identify the variables that were
significantly associated with stimulant
use (P  0.05).
It should be noted that prevalence
estimates are weighted and therefore
not in exact agreement with estimates





Data on some CBCL scale scores were
missing for 342 children. A comparison
of the age, sex and family structure of
children with complete data and those
with missing data showed that the only
significant difference between the
groups was that the latter were less
commonly living with their family of
origin (75% v 68%). Some CBCL data
were missing for 2/52 children with
ADHD who were receiving stimulants
and 31/345 children with ADHD who
were not receiving stimulants. Informa-
tion about diagnostic status (ie, whether
or not children had ADHD, based on
DISC-IV responses) was missing for 35
children. These children had signifi-
cantly higher scores on the Externalis-
ing and Attention Problems scales of
the CBCL and were significantly older
(mean, 11.4 years [95% CI, 10.2–
12.6]) than other children in the study
(mean, 9.4 years [95% CI, 9.3–9.5]).
There were also data missing for demo-
graphic items, particularly for the ques-
tion asking about parental income, to
which 30% of parents did not provide a
response. For these reasons, the number
of participants varies in some analyses.
Medications used
Eighty-six children (2.4%; 95% CI,
1.9%–2.9%) had received medication
for emotional and behavioural prob-
lems. Among those who had taken med-
ication, 68 (79%) had taken one
medication, 13 (15%) had taken two
medications, four (5%) three medica-
tions, and one child had taken five
psychotropic medications. An addi-
tional seven children had been treated
with herbal remedies.
The medications most commonly
used were stimulants (dexamphetamine
or methylphenidate) (1.8% [68/3597];
95% CI, 1.5%–2.3%), antidepressants
(0.4% [13/3597]; 95% CI, 0.2%–0.6%)
and clonidine (0.2% [10/3597]; 95%
CI, 0.1%–0.4%). Three children had
been treated with thioridazine, two with
risperidone, two with sodium valproate,
and two with other mood stabilisers.
Among the 13 children treated with
antidepressants, nine had received a
selective serotonin reuptake inhibitor,
two a tricylic antidepressant, one
moclobemide, and one an unidentified
antidepressant. Although not included
in our analysis because diagnostic data
were not obtained for 4- and 5-year-old
children, 0.5% (5/912) of 4–5-year-olds
had received stimulants.
Interviewers asked parents to explain
why their children were being pre-
scribed each medication. The majority
of parents of children receiving stimu-
lants said that the medication was for
“ADD” or “ADHD”. One child was
said to be receiving the medication for
“autism”, one for “developmental
delay”, one for “a chemical imbalance
in the brain”, while for one child the
reason was not given. Parents reported
that antidepressants were largely being
used to treat “depression” and/or “anxi-
ety”, while clonidine was described as
being used to treat “ADD”, “ADHD”
or “sleeping problems”.
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Children with ADHD
Among 6–17-year-olds, the prevalence
of ADHD (based on DISC-IV data)
was 11.2% (95% CI, 10.2%–12.2%)
(5.8% “inattentive”, 2.0% “hyperac-
tive” and 3.3% “combined” subtypes).
Overall, 12.6% (95% CI, 9.8%–
16.1%) of children with ADHD were
being treated with stimulants. The prev-
alence of stimulant treatment according
to ADHD subtype, sex and age group is
presented in Box 1. A further 2.3%
(95% CI, 1.3%–4.3%) of the children
were being treated with antidepressants
and 1.9% (95% CI, 0.9%–3.6%) with
clonidine. Four children with ADHD
had been treated with sodium valproate
or another mood stabiliser, one with
thioridazine, and one with risperidone.
While the percentage of children
receiving stimulants who did not meet
the criteria for ADHD was small (0.5%;
95% CI, 0.3%–0.8%), they represented
22.9% (95% CI, 14.6%–34.0%) of all
the chi ldren taking st imulants.
Although not meeting the criteria for
ADHD, this latter group had a signifi-
cantly higher mean score on the CBCL
Externalising Scale (mean, 56.1; 95%
CI, 50.8–61.3) than those not receiving
stimulants (mean, 46.0; 95% CI, 45.7–
46.4). They also had significantly higher
scores for the Attention Problems Scale
(on stimulants, 60.7 [95% CI, 55.6–
65.7]; off stimulants, 53.2 [95% CI,
52.9–53.4]) and the Aggressive Behav-
iour Scale (on stimulants, 57.5 [95%
CI, 53.4–61.5]; off stimulants, 52.6
[95% CI, 52.4–52.8]).
Demographic characteristics and 
use of services by children receiving 
stimulants
A higher proportion of children taking
stimulants were living in low-income,
single-parent, blended or “other” fami-
lies (eg, living with relatives), and fami-
lies with unemployed parents. They had
also attended various health services
more often than other children (Box 2).
However, when all these variables were
entered in a logistic regression model in
which stimulant use was the dependent
variable, the only factors that remained
significantly associated with stimulant
use were the child’s sex (male) and
having had consultations with a paedia-
trician (Box 3).
1: Proportion (95% CI) of children being treated with stimulants, by ADHD subtype, sex and age
Boys Girls Total
ADHD subtype (n = 397)
  Inattentive (n = 205)
  Impulsive/hyperactive (n = 73)











  All ages (with any ADHD subtype) (n = 397)
  6–12-year-olds (with any ADHD subtype) (n = 292)
  13–17-year-olds (with any ADHD subtype) (n = 105)













ADHD = attention-deficit/hyperactivity disorder.
2: Demographic characteristics and attendance at services, according to stimulant treatment 




(n = 3529) P








Age (n = 3596)
  6–12 years






Low income (< $680 per week before tax) (n = 2536) 58.9% (45.9%–70.8%) 39.7% (37.9%–41.6%) 0.004
Single-parent/step-blended/“other” family (n = 3593) 36.6% (26.4%–48.2%) 26.1% (24.7%–27.5%) 0.05
Father’s schooling to age <16 years (n = 2634) 29.8% (18.7%–44.0%) 30.8% (29.1%–32.6%) 0.8
Mother’s schooling to age <16 years (n = 3056) 43.3% (32.1%–55.2%) 30.4% (28.9%–32.0%) 0.02
Father unemployed (n = 2700) 26.0% (15.9%–39.6%) 14.4% (13.2%–15.7%) 0.02
Mother unemployed (n = 3182) 56.9% (44.8%–68.2%) 44.7% (43.0%–46.4%) 0.05
Services attended (in previous six months)
  School counsellor (n = 3592)
  Family doctor (n = 3590)
  Paediatrician (n = 3590)
  Psychologist/social worker (n = 3592)
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Clinical characteristics of children 
receiving stimulants
The odds ratio (OR) for stimulant use
among children with a diagnosis of
ADHD relative to those without this
diagnosis was 30.5 (95% CI, 16.9–
55.1); for those with conduct disorder
the OR was 13.8 (95% CI, 7.6–25.1);
and for those with depressive disorder it
was 4.7 (95% CI, 2.2–10.2). The ORs
for scores on all the CBCL scales were
also significant (Box 4).
A series of forwards and backwards
stepwise logistic regression analyses
were employed to identify a parsimoni-
ous model of predictor variables (ie, one
that achieves the simplest explanation).
In these analyses, stimulant use was the
response variable. Attendance at a pae-
diatrician, the child’s sex, diagnosis (ie,
ADHD, conduct disorder or depressive
disorder) and the full set of CBCL scale
scores were the explanatory variables.
Inclusion of both the children’s diag-
noses and their CBCL scores made it
possible to determine whether the
severity of children’s problems was asso-
ciated with stimulant use, independent
of diagnosis. The variables identified
using the forwards and backwards pro-
cedures were identical. Children receiv-
ing stimulants were significantly more
likely to have attended a paediatrician,
to be male, to have ADHD, and to have
a higher score on the Attention Prob-
lems Scale and Aggressive Problems
Scale of the CBCL than children not on
stimulants (Box 5). The adjusted OR
for the score on the CBCL Anxious/
Depressed Scale was significantly less
than one, suggesting that the presence
of anxiety/depression is associated with
a lower likelihood of stimulant use after
adjusting for the other variables in Box
4. The lower adjusted OR for ADHD in
this multivariate analysis reflects the
close relationship between having a high
score on the Attention Problems Scale
and being diagnosed with ADHD.
DISCUSSION
1.Discussion
To the best of our knowledge, this
survey is the first Australia-wide study
examining the prevalence of psycho-
tropic medication use by children and
adolescents. Previous Australian and
overseas studies have been confined to
geographically circumscribed regions or
to clinic populations.1,5,7
The proportion of children using psy-
chotropic medications in our study
(2.4%) was comparable to that reported
by Jensen et al1 for children in the
United States (2.3%). In both studies
the most frequently used medications
were stimulants, followed by anti-
depressants, with only a very small
number of children being prescribed
other medications. The percentage of
those with ADHD who were taking
stimulants was similar in the two studies
(12.6% [our study] versus 12% [Jensen
et al]) but considerably smaller than
that reported by Angold et al (72%).7 It
is possible that the higher rate identified
in the study by Angold et al reflects a
regional variation in prescribing pat-
terns.
About half the children using stimu-
lants in the two US studies did not meet
the diagnostic criteria for ADHD,1,7
compared with 23% in our study. The
discrepancy almost certainly reflects the
use of the broader DSM-IV criteria in
our study rather than the narrower
DSM-III-R criteria14 used in both US
studies. When DSM-III-R criteria are
used, fewer children are identified as
having ADHD.15,16 The effect of using
narrower criteria can be observed in the
present study, where, if only ADHD
combined subtype (broadly equivalent
to ADHD in DSM-III-R and hyper-
kinetic disorder in ICD-10)16,17 is used
to identify those with ADHD, the pro-
portion of children without ADHD
receiving stimulants increases to 57%
(38/67).
Are children in Australia being under-
treated or overtreated with stimulant
4: Odds ratios for stimulant use in 
children per CBCL scale point 
(n=3255)*
CBCL scale Odds ratio (95% CI)
Total Problem Scale 1.135 (1.110–1.160)
Externalising Scale 1.134 (1.110–1.159)























* The odds ratio (and its confidence interval) for a 
given increase (say, n points) can be estimated 
by raising the estimates in the table to their nth 
power. CBCL = Child Behaviour Checklist.
3: Simple and adjusted odds ratios for stimulant use in children, by 
demographic characteristics and service use (n=1865)*
Simple odds ratios 
(95% CI)




  6–12 years
  Low income (< $680 per week before tax)
  Single-parent/step-blended/“other” family
  Father’s schooling to age < 16 years
  Mother’s schooling to age < 16 years
  Father unemployed

















Services attended (in previous six months)
  School counsellor
  Family doctor
  Paediatrician












*Data were missing from some categories (see Box 2 for details). †Controlling for the effect of the other 
variables in the table.
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medication? The answer to this question
depends on the criteria used to assess
the appropriateness of stimulant use by
children. As noted by Jensen et al,1 a
diagnosis of ADHD alone is a relatively
crude criterion for determining the
appropriateness of stimulant use. In our
study a substantial proportion of chil-
dren using stimulants did not meet even
the broader DSM-IV criteria for a diag-
nosis of ADHD. However, parents iden-
tified many of these children as having a
substantial number of externalising
problems (eg, attention problems and
aggressive behaviour). It is possible that
these children have subsyndromal forms
of ADHD. Alternatively, stimulant
treatment may have reduced the origi-
nal severity of their symptoms, or other
behavioural problems may have been
misdiagnosed as ADHD.
Even among those diagnosed with
ADHD there is debate about the extent
to which treatment should include the
use of stimulant medication. For exam-
ple, the National Institute for Clinical
Excellence in the United Kingdom rec-
ommends that methylphenidate should
only be used to treat children with
“severe ADHD” (described as being
equivalent to severe combined-type
ADHD).18 The guidelines estimate that
about 1% of children in the community
have this severe form of the disorder.
This is substantially less than the 1.8%
of children receiving stimulants in Aus-
tralia. In contrast, recommendations
published by the American Academy of
Child and Adolescent Psychiatry sug-
gest that the decision to medicate
should be based on a diagnosis of
ADHD (based on DSM-IV criteria) and
persistent target symptoms that cause
functional impairment at school and
usually also at home and with peers.19 If
these criteria were employed to assess
the appropriateness of stimulant use, it
might be concluded that children in
Australia are undermedicated.
One of the limitations of our study
was that, in some areas, substantial
amounts of data were missing. If, as
seems likely, the children with missing
data had a higher rate of mental health
problems, we may be underestimating
the prevalence of ADHD and psycho-
tropic medication use by Australian
children. Other limitations included the
lack of information about the dosage of
medication children were taking, the
lack of reports from teachers and the
lack of information about who was pre-
scribing the medication.
Despite these limitations, the picture
of psychotropic medication use by chil-
dren is broadly consistent with clinical
practice in Australia: paediatricians play
an important role in managing children
with ADHD, and stimulant medication
is commonly prescribed for attention
problems and disruptive behaviour.
There is a great need to clarify the
circumstances under which stimulant
medication should be used as part of the
treatment of ADHD. This will require
additional information about the degree
to which children with different types or
severities of ADHD are disadvantaged
as a result of their disorder and the
extent to which stimulant medication
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5: Variables significantly related 





























*After forward stepwise logistic regression.
†Per unit scale score, the odds ratio (and its 
confidence interval) for a given increase (say, n 
points) can be estimated by raising the estimates 
in the table to their nth power.
ADHD = Attention-deficit/hyperactivity disorder. 
DSM-IV = Diagnostic and statistical manual of 
mental disorders, 4th ed.10
